Navigation Links
Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Date:9/17/2009

apies that help patients get to a healthier blood pressure range," said John Flack, M.D., Valturna investigator, and Chairman of the Department of Internal Medicine, Wayne State University, Detroit. "Now for the first time, we have a treatment option in one pill that targets two key points of the RAAS, which may be overactive in many hypertensive patients."

This approval was primarily based on a pivotal eight-week randomized, double-blind, placebo-controlled clinical trial in approximately 1,800 patients, which studied aliskiren 150 mg and 300 mg and valsartan 160 mg and 320 mg alone and in combination. The initial doses of aliskiren and valsartan were 150 mg and 160 mg, respectively, and were increased at four weeks to 300 mg and 320 mg, respectively. Blood pressure reductions with the aliskiren/valsartan combination were significantly greater than with the monotherapies or placebo at the eight-week primary endpoint. Mean systolic and diastolic blood pressure reductions from baseline were 17.2/12.2 mmHg for aliskiren 300 mg/valsartan 320 mg, compared with 12.8/9.7 mmHg for valsartan 320 mg, 13.0/9.0 mmHg for aliskiren 300 mg, and 4.6/4.1 mmHg for placebo (p<0.05 for aliskiren/valsartan vs monotherapies or placebo).

The single-pill combination Valturna targets the RAAS in two ways. The valsartan component blocks, at the receptor level, the action of angiotensin II, an important end product of the RAAS that causes blood vessels to tighten and narrow. The aliskiren component reduces angiotensin II levels by directly inhibiting renin, an enzyme produced by the kidneys that starts a process which leads to formation of angiotensin II. An overactive RAAS is an important contributor to high blood pressure in many patients. By targeting two key points within the RAAS, Valturna helps blood vessels relax and widen so blood pressure is lowered.

Research suggests that up to 85% of hypertensive patients may need multip
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
2. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
5. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... -- Bone Biologics, Corp., ("Bone Biologics") announced today the completion ... Capital") of Los Angeles, CA. The ... regenerative medicine using the patented recombinant human protein known as ... Michael Schuler , CEO of Bone ... round of funding which will allow the company to continue ...
(Date:5/6/2015)... San Jose, California (PRWEB) May 06, 2015 ... – Quantum Dots, a type of nanomaterial with ... the fastest-growing product in the global nanophotonics materials ... properties of quantum dots due to quantum confinement ... use in a wide range of scientific, technological, ...
(Date:5/6/2015)... -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of ... Cassian Yee , M.D., Professor, Department of Melanoma ... of Texas MD Anderson Cancer Center joined its scientific ... Immunology, Division of Cancer Medicine, and Director, Solid Tumor ... University of Texas MD Anderson Cancer Center.  ...
(Date:5/6/2015)... , May 6, 2015 Dr Jaspreet ... Massey University, will deliver a speech at the 2015 Asian ... the Shanghai New Expo Center.  ... introduce to attendees the topic: ,Potato Starch: A Potential ... Smart Foods., Co-editor of a 528 page ...
Breaking Biology Technology:Bone Biologics Corp Completes Financing With Hankey Capital, LLC 2Bone Biologics Corp Completes Financing With Hankey Capital, LLC 3Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 2Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 3Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2
... asking for bids on the construction of downtown wireless Internet access ... to charge user fees and would take on the cost of ... for the right to operate. The project would not be paid ... costs are still not finalized. , ,Now, though, the city is ...
... Wis. While the Madison chapter of the ... for new social and technological developments, Scott Converse showed them ... they want to see where the next big thing is ... UW-Madison School of Business and founder of the Web integration ...
... is full of excitement and anticipation of what may await them ... screen the final onslaught of companies vying for a place at ... February to unwrap the selected 70 or so companies that will ... way that just wont wait until the conference gems we ...
Cached Biology Technology:Madison asks for wireless bids; airport, downtown would be first 2Business-school IT director points to reasons for wireless trend 2An early Christmas gift 2
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... 20, 2012   Cell Therapeutics, Inc. ("CTI") (NASDAQ and ... European Medicines Agency,s ("EMA") Committee for Medicinal Products for ... on CTI,s Marketing Authorization Application ("MAA") for Pixuvri in ... with the CHMP on the Summary of Product Characteristics ...
... of scientists has found one of the rarest and least ... was believed to be extinct or on the verge of ... of Primatology , confirms the continued existence of this endangered ... it was previously not known to exist. Miller,s Grizzled ...
... flow channels offer a chemically unique environment, which at first ... in the crust of the earth, through which water flows, ... And yet it is precisely this extreme environment, where ... root of all life: The multiplication of biomolecules (reproduction) and ...
Cached Biology News:Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 2Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February 3'Extinct' monkey rediscovered in Borneo by new expedition 2Avalanche of reactions at the origin of life 2Avalanche of reactions at the origin of life 3
... while maintaining high cell viability , ... , Fast: less than one ... , Highly reproducible results from ... with the Bio-Rad Gene Pulser Xcell System ...
Trypsin (Pig Pancreas) (TPCK Treated, Highly Purified)...
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse P-Selectin/CD62P MAb (Clone 127933)...
Biology Products: